Jay Brad­ner’s NI­BR ex­it sets off a suc­ces­sion plan at Mer­ck; Dyne and Mor­phoSys fill ma­jor R&D roles

→ In the Big Phar­ma world, com­pa­nies like J&J and Mer­ck have ex­pe­ri­enced a pro­nounced sea change in lead­er­ship over a two-year pe­ri­od, and you …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.